The clinical guidance for patients on GLP-1 and GIP receptor agonists is to target 60 to 75 grams of protein per day, and up to 1.5 grams per kilogram of body weight on an individualized basis
Tirzepatide monotherapy in type 2 diabetes (SURPASS-1)
Another issue involves patient expectations
Those on blood pressure medications, anticoagulants, or medications requiring specific stomach emptying rates should inform their prescriber, as GLP-1 medications slow gastric transit and may alter absorption rates
Rilonacept 160 and goflikicept, 161 which act as soluble decoy receptors, bind to IL-1 and IL-1 with high affinity, preventing their interaction with IL-1R and mitigating downstream inflammatory responses
Timeline: develops gradually over weeks to months of repeated injection in the same area